Indraprastha Medical Corporation Limited has scheduled a series of one-on-one meetings with investors and analysts in Mumbai on June 4 and 5, 2026. The management intends to engage with representatives from various mutual funds and Portfolio Management Services (PMS) companies to discuss the company's performance and outlook. The initiative is undertaken pursuant to Regulation 30 and 46 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

The meetings will facilitate direct engagement with key institutional investors, including HDFC Mutual Fund, AXIS Mutual Fund, PineBridge Investments, and Birla Mutual Fund. Other participants include Nippon Mutual Fund, SBI Mutual Fund, UTI Mutual Fund, InCred AMC, and Grow Mutual Fund. Additionally, the management will meet with PMS firms such as Kriis PMS, Alfaccurate PMS, and Emkay PMS.

The company clarified that the schedule is subject to change due to exigencies on the part of the investors or the company. Furthermore, Indraprastha Medical Corporation Limited stated that no unpublished price sensitive information pertaining to the company will be shared during the meet. The disclosure was filed by Priya Ranjan, AVP – Corporate Affairs & Legal and Company Secretary & Compliance Officer.

Investor Meet Schedule

Indraprastha Medical Corporation Limited reported its audited financial results for the year ended March 31, 2026, following a board meeting held on May 12, 2026. The company posted a net profit (PAT) of ₹183.62 crore for the fiscal year, up from ₹160.99 crore in the previous year. Revenue from operations grew to ₹1482.51 crore from ₹1356.36 crore, while total income rose to ₹1511.26 crore from ₹1379.01 crore. The board also recommended a dividend of 40%, translating to ₹4.00 per equity share for FY2025-26, subject to shareholder approval at the Annual General Meeting. In the previous financial year, the company had declared a dividend of 45%, or ₹4.50 per share. Pursuant to Regulation 30 read with Schedule III (Part A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published a public notice of its financial results on May 13, 2026, in the "Financial Express" (all India editions, English) and "Jansatta" (Delhi edition, Hindi).

Annual Financial Performance

The company's full-year results reflect broad-based growth across key metrics. Total expenses for the year stood at ₹1265.24 crore compared to ₹1162.69 crore in the prior year, while profit before tax rose to ₹246.02 crore from ₹216.32 crore. Basic and diluted earnings per share improved to ₹20.03 from ₹17.56. The following table summarises the annual financial performance:

Quarterly Performance

For the quarter ended March 31, 2026, the company recorded a net profit of ₹41.70 crore, marginally higher than ₹41.01 crore in the corresponding quarter of the previous year. Revenue from operations for the quarter increased to ₹364.81 crore from ₹333.75 crore, while total expenses were reported at ₹317.13 crore. However, the quarter saw a contraction in profitability margins, with EBITDA declining to ₹604 million from ₹615 million in the year-ago period. The EBITDA margin narrowed to 16.57% from 18.41% on a year-on-year basis, indicating higher cost pressures at the operating level during the quarter.

Balance Sheet Highlights

As at March 31, 2026, total assets stood at ₹991.36 crore compared to ₹851.62 crore in the previous year. Non-current assets increased to ₹574.77 crore from ₹420.49 crore, driven by growth in property, plant and equipment to ₹330.96 crore and financial assets to ₹203.50 crore. Total equity rose to ₹740.37 crore from ₹596.68 crore, reflecting the improved profitability. Cash and cash equivalents stood at ₹4.93 crore as at March 31, 2026, compared to ₹61.48 crore in the prior year, with the decline attributable to higher investing activities.

Cash Flow Summary

Net cash generated from operating activities for the year stood at ₹167.44 crore, up from ₹156.75 crore in the prior year. The company used ₹177.61 crore in investing activities, primarily on account of purchase of property, plant and equipment (net of sale) of ₹59.65 crore and movement in other bank balances of ₹143.93 crore. Net cash used in financing activities amounted to ₹46.38 crore, including dividend paid of ₹41.03 crore.

Regulatory Compliance and Audit

The company confirmed that it does not fulfil the criteria specified under SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, and SEBI Circular No. DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023, and therefore does not fall under the definition of a "Large Corporate". The statutory auditors, S N Dhawan & CO LLP, provided an unmodified opinion on the annual audited financial results. The company operates in a single segment, Healthcare, and does not have any subsidiary, associate, or joint venture companies as of March 31, 2026. The board meeting commenced at 3:00 p.m. and concluded at 4:35 p.m. The New Labour Codes, made effective from November 21, 2025, have been accounted for with the incremental estimated liability recognised in the current year's financial results. The newspaper advertisement was submitted to BSE Limited and the National Stock Exchange of India Limited on May 13, 2026, by Priya Ranjan, AVP – Corporate Affairs & Legal and Company Secretary & Compliance Officer.